Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides

1 Mar 2023

Abstract excerpt

Development of potent and broad-spectrum antivirals against SARS-CoV-2 remains one of top priorities, especially in the case of that current vaccines cannot effectively prevent viral transmission. We previously generated a group of fusion-inhibitory lipopeptides, with one formulation being evaluated under clinical trials. In this study, we dedicated to characterize the extended N-terminal motif (residues...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to interferon and immune responses
Share to SARS-CoV-2 and COVID-19 Research
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36868315
DOI: 10.1016/j.antiviral.2023.105571

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptidesPMID 36868315Read ↗

Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the pre-hairpin intermediate of the spike proteinSemantic proximity Read ↗

Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusionSemantic proximity Read ↗

Discovery of New Fusion Inhibitor Peptides against SARS-CoV-2 by Targeting the Spike S2 SubunitSemantic proximity Read ↗

A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of ConcernSemantic proximity Read ↗

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigenSemantic proximity Read ↗

Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccinesSemantic proximity Read ↗

A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potentialSemantic proximity Read ↗

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including OmicronSemantic proximity Read ↗

Antiviral Peptides as Promising Therapeutics against SARS-CoV-2Semantic proximity Read ↗

Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluationSemantic proximity Read ↗

SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host CellsSemantic proximity Read ↗

Targeting an evolutionarily conserved “E-L-L” motif in the spike protein to develop a small molecule fusion inhibitor against SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.